RESEARCH TRIANGLE PARK, N.C.–(BUSINESS WIRE)– Quintiles heeft vandaag zijn nieuwe dienstenpakket Continuous Glucose Monitoring (CGM) geïntroduceerd. Deze nieuwe oplossing combineert innovatieve, draagbare technologie met Quintiles’ verregaande therapeutische en analytische expertise, om de efficiëntie en kwaliteit van onderzoeken naar diabetesbehandelingen te verhogen.
Het nieuwe CGM-aanbod verschaft onderzoekers via het prijswinnende technologieplatform Quintiles Infosario® toegang tot een veelheid van op maat gemaakte data-analysemiddelen en prestatierapporten. Deze geoptimaliseerde reeksen met glycemische data zijn zodoende efficiënter te analyseren, waardoor afwijkende trends of potentiële veiligheidsrisico’s eerder aan het licht komen dan met traditionele modellen voor diabetescontrole.
Quintiles Introduces Continuous Glucose Monitoring Services to Improve Diabetes Outcomes
RESEARCH TRIANGLE PARK, N.C.–(BUSINESS WIRE)– Quintiles today announced the launch of its new Continuous Glucose Monitoring (CGM) service offering. This new solution combines innovative, wearable technology with Quintiles’ deep therapeutic and analytical expertise to help enhance the efficiency and quality of diabetes-focused clinical trials.
When used in clinical research, the new CGM offering will provide investigators with access to a myriad of customized data analytics and performance reports through its award-winning Quintiles Infosario ® technology platform. These optimized glycemic data sets can be analyzed more efficiently to uncover trends such as non-compliance and potential safety triggers faster than traditional diabetes monitoring models. In addition, Quintiles experts from the company’s Diabetes Center of Excellence will provide dedicated support for the offering – combining data and therapeutic expertise to drive smarter protocol design and enhance patient safety and compliance.
“According to the International Diabetes Federation (IDF), every six seconds, a person dies from diabetes-related causes and almost half of those deaths are people under the age of 60,” said Margaret Keegan, president of Data Sciences, Safety and Regulatory Services at Quintiles. “With diabetes diagnoses on the rise, the need for innovative and accessible treatments also increases. CGM can provide a variety of in-depth measures from diabetes patients – information that can be used to enhance the way patients are treated for diabetes and why this new offering is so critical.”
Through the offering, continuous glucose measurements will be captured by a wearable sensor and wirelessly sent to a receiver, recording readings throughout the day. In the clinical trial setting, this comprehensive and timely glucose visibility has the potential to improve patient safety, accelerate clinical development and provide a basis for differentiated claims.
“We are excited to bring this new CGM offering to the market as a complement to Quintiles’ technology integration strategy,” said Sam Osman, head of Cardiac Safety Services at Quintiles. “We believe this new technology solution incorporating biosensors and wearables, which can be used across all drug development phases, will improve the way the industry tracks and improves diabetes care for patients worldwide.”
To learn more about Quintiles Continuous Glucose Monitoring, visit quintiles.com/cgm.
Quintiles (NYSE: Q) helps biopharma and other healthcare companies improve their probability of success by connecting insights from our deep scientific, therapeutic and analytics expertise with superior delivery for better outcomes. From advisory through operations, Quintiles is the world’s largest provider of product development and integrated healthcare services, including commercial and observational solutions. Conducting operations in approximately 100 countries, Quintiles is a member of the FORTUNE 500 and has been named to FORTUNE’s list of the “World’s Most Admired Companies.” To learn more, visit www.quintiles.com.